MYC and Miyoshi myopathy: In the light of the anticancer potential of mitochondrial inhibitors targeting molecular mechanisms of MYC, tigecycline warrants further development, given its potentially low on-target toxicity, avoiding proteasome inhibitors resistances and/or MM relapse.